Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

As is cus­tom, an EMA pan­el on Fri­day is­sued its week­ly rec­om­men­da­tions on mar­ket­ing ap­pli­ca­tions sub­mit­ted by drug de­vel­op­ers. This week, the agency backed the use of five new ther­a­pies — in­clud­ing two No­var­tis drugs — but is­sued no neg­a­tive re­views.

No­var­tis’ S1P drug for re­laps­ing forms of mul­ti­ple scle­ro­sis (MS) drug, Mayzent (known chem­i­cal­ly as sipon­i­mod), which was ap­proved by the FDA in March — has been giv­en the nod by the EMA. The Swiss drug­mak­er al­ready sells its oth­er MS drug, Gilenya, in both re­gions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.